Core Insights - China's top antitrust body has initiated a probe into competition practices in the food delivery sector, leading to a rise in shares of major companies like Meituan, Alibaba, and JD.com [1][4] Group 1: Market Reactions - Meituan's stock increased by 6.6%, marking its largest gain since May 29, while Alibaba's shares rose by 5.3% and JD.com's shares gained over 2% [1] - The overall sentiment in the Chinese tech sector was positive, with the Hang Seng Tech Index climbing by 3.1% [6] Group 2: Regulatory Actions - The State Council's anti-monopoly committee will investigate competition behaviors among delivery platforms through on-site checks, interviews, and surveys, as per the State Administration for Market Regulation [3] - Increased scrutiny is expected to support industry margins by curbing subsidy-led expansion and raising compliance costs for new entrants [2] Group 3: Industry Context - Since 2025, Beijing has intensified scrutiny of the retail sector due to significant investments in subsidies by major players like Alibaba, Meituan, and JD.com, which led to aggressive price wars [4] - Investors are optimistic that the ongoing probe will help mitigate the rampant discounting and subsidies that have negatively impacted profit margins for these companies [4]

Investment Rating - The stock rating for JD Health International Inc. is Underweight [5] - The industry view is Attractive [5] Core Insights - JD Health International Inc. maintained its 2025 targets despite a strong performance in Q1 2025, aiming for mid-teens revenue growth and flat operating profit [3][8] - The company expects over 20% growth in drug sales, mid-teens growth in nutritional products, and high single-digit growth in medical devices for the full year 2025 [3] - The gross profit margin (GPM) is anticipated to improve due to supply chain management efficiencies and increased advertising income, particularly in nutritional products [3] - JD Health's strategic focus includes enhancing B2C drug sales, especially for originator drugs, which currently represent approximately 30% of total drug sales [4] - The company plans to increase offline investments through greenfield projects rather than large-scale mergers and acquisitions [4] Financial Performance - In Q1 2025, JD Health reported revenue of RMB 16.6 billion, reflecting a year-over-year increase of 25.5%, which was 11% above consensus estimates [8] - The adjusted operating profit grew by 73% year-over-year to RMB 1.31 billion, with an adjusted operating profit margin of 7.9%, up 2.2 percentage points year-over-year [8] - Adjusted net profit rose by 47.7% year-over-year to RMB 1.77 billion, with an adjusted net margin of 10.6% [8]